World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
42904
World Ranking
11559
National Ranking
431

Sergio Amadori publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Sergio Amadori sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 486 publications — 56th percentile

56% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Sergio Amadori D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Sergio Amadori sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Sergio Amadori is affiliated with the University of Rome Tor Vergata in Italy and focuses primarily on research in medicine with an emphasis on hematology. Their academic work includes exploration of genetics, public health, environmental and occupational health, molecular biology, and cancer research.

The scientist's research concentrates on a range of topics within hematology, especially acute myeloid leukemia and other leukemia-related fields. Main topics covered in their work include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Cancer Genomics and Diagnostics
  • Hematopoietic Stem Cell Transplantation
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Amadori has published extensively in various peer-reviewed journals. Frequent publication venues comprise:

  • Clinical Lymphoma Myeloma & Leukemia
  • Blood
  • HemaSphere
  • Leukemia
  • Blood Advances

Several recent papers include the following works:

  • Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial, 2023, The Lancet
  • Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial, 2021, Leukemia
  • Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results, 2021, Leukemia
  • Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial, 2020, Blood Advances
  • Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study, 2020, The Lancet Haematology

Amadori collaborates regularly with a number of researchers in the field. Frequent co-authors include:

  • Richard F. Schlenk
  • Hervé Dombret
  • Pau Montesinos
  • Harry P. Erba
  • Elżbieta Patkowska

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

    Hartmut Dohner;Elihu H. Estey;Sergio Amadori;Frederick R. Appelbaum

  • Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

    Richard M. Stone;Sumithra J. Mandrekar;Ben L. Sanford;Kristina Laumann

  • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia

    F. Lo-Coco;G. Avvisati;M. Vignetti;C. Thiede

  • Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

    Roberto Stasi;Adalberto Pagano;Elisa Stipa;Sergio Amadori

  • Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.

    Giampaolo Bucaneve;Alessandra Micozzi;Francesco Menichetti;Pietro Martino

  • Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.

    Francois Guilhot;Jane Apperley;Dong-Wook Kim;Eduardo O. Bullorsky

  • Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice

    Eliane Gluckman;Vanderson Rocha;William Arcese;Gérard Michel

  • Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial

    Stefan Suciu;Franco Mandelli;Theo de Witte;Robert Zittoun

  • Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell–depleting therapy with rituximab

    Roberto Stasi;Nichola Cooper;Giovanni Del Poeta;Elisa Stipa

  • Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura**

    Roberto Stasi;Elisa Stipa;Mario Masi;Manrico Cecconi

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)

    Giovanni Del Poeta;Adriano Venditti;Maria Ilaria Del Principe;Luca Maurillo

  • Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study.

    Luciana Annino;Maria Luce Vegna;Andrea Camera;Giorgina Specchia

  • Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review

    Roberto Stasi;Ameet Sarpatwari;Jodi B. Segal;John Osborn

  • The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura

    Nichola Cooper;Roberto Stasi;Susanna Cunningham-Rundles;Michael A. Feuerstein

  • Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

    Uwe Platzbecker;Giuseppe Avvisati;Laura Cicconi;Christian Thiede

  • Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.

    Mandelli F;Avvisati G;Amadori S;Boccadoro M

  • IKZF1 (Ikaros) Deletions in BCR-ABL1–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report

    Giovanni Martinelli;Ilaria Iacobucci;Clelia Tiziana Storlazzi;Marco Vignetti

  • Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management

    Roberto Stasi;Maria Laura Evangelista;Elisa Stipa;Francesco Buccisano

Frequent Co-Authors

Franco Mandelli
Franco Mandelli Sapienza University of Rome
Francesco Lo-Coco
Francesco Lo-Coco University of Rome Tor Vergata
Stefan Suciu
Stefan Suciu European Organisation for Research and Treatment of Cancer
Valter Gattei
Valter Gattei University of Trieste
Theo de Witte
Theo de Witte Radboud University
Richard F. Schlenk
Richard F. Schlenk University Hospital Heidelberg
Hartmut Döhner
Hartmut Döhner University of Ulm
William Arcese
William Arcese Sapienza University of Rome
Miguel A. Sanz
Miguel A. Sanz University of Valencia
Giorgina Specchia
Giorgina Specchia University of Bari Aldo Moro

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a wide variety of rewarding online degrees and healthcare career paths. Many students begin their journey through flexible programs that don’t require extensive entry testing. For example, you can start your nursing career by enrolling in an lpn program no entrance exam, providing an accessible route to licensed practical nursing.

If you're interested in leadership roles, consider a health care administration degree online. This option is ideal for those aiming to manage healthcare facilities or oversee medical operations without transitioning to clinical work.

Nurses aiming to advance their education can choose an adn to np bridge program, moving efficiently from an associate degree in nursing to nurse practitioner status. These programs help registered nurses step into advanced practice roles without starting from scratch.

Additionally, students seeking to specialize in wellness and patient education may benefit from an online degree in nutrition. This pathway prepares graduates for roles in clinical nutrition, dietetics, or health policy, supporting holistic patient care.

Best Scientists Citing Sergio Amadori

Trending Scientists

Recently Published Articles